glp-1 receptor agonists effects on cardiovascular risk reduction and mortality outcomes with vs other glucose-lowering drugs in individuals with NAFLD and type 2 diabetes: a large population-based matched cohort study | Diabetologia GLP-1 Agonists in Cardiovascular Diseases:
Description
Clinical practice guidelines for the management of constipation in adults
Fujita H, Morii T, Fujishima H, et al
But coverage changes
2020;3:e2020969
The numbers tell the story: patients on these medications have higher rates of retained gastric contents during esophagogastroduodenoscopy (EGD) compared to non-users 8.07% versus 3.49% [14]
